Global Acute Myeloid Leukemia Treatment Market 2020-2029 (Includes Business Impact of COVID-19)

                                          
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. AML is a complex and challenging disease with generally low survival rates.

The global Acute Myeloid Leukemia Treatment market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026.
This report focuses on Acute Myeloid Leukemia Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Myeloid Leukemia Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:


 	
Ambit Biosciences Corporation
 	
Celgene Corporation
 	
Cephalon
 	
Clavis Pharma
 	
Eisai
 	
Genzyme Corporation
 	
Sunesis Pharmaceuticals

Segment by Regions

 	
North America
 	
Europe
 	
China
 	
Japan

Segment by Type

 	
DC regimen
 	
AVD Regimen
 	
VCD regimen

Segment by Application

 	
Hospital
 	
Clinic
 	
Others

In October 2020, AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. The FDA previously granted accelerated approval to VENCLEXTA for this indication in 2018.

The cost for Venclexta oral kit (50 mg-100 mg) is around $3,200 for a supply of 30 kits.

VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. VENCLEXTA is approved in more than 50 countries, including the U.S.

In July 2020, European Commission Approved DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).

Pfizer Inc. (NYSE:PFE) announced that the European Commission approved DAURISMO™ (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.

The approval follows the medicine’s positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) earlier this year, as well as the medicine’s approval by the U.S. Food and Drug Administration (FDA) in November 2018.

The European Commission’s approval of DAURISMO is based on results from the Phase 2 BRIGHT 1003 trial, which showed DAURISMO nearly doubled median overall survival compared to LDAC alone (8.3 months vs. 4.3 months, HR 0.463, 95% CI [0.299,0.717]) in patients with previously untreated (de novo or secondary) AML who were not eligible for intensive chemotherapy. The difference represented a 54 percent reduction in the risk of death for patients treated with DAURISMO plus LDAC (HR: 0.463, 95% CI: 0.299, 0.717, one-sided p-value 0.0002)

DAURISMO in combination with low-dose cytarabine nearly doubled overall survival compared to low-dose cytarabine alone. People with previously untreated acute myeloid leukemia who cannot withstand intensive chemotherapy are in urgent need of new options and using this new therapy that may extend survival for appropriate patients.

DAURISMO is a once-daily oral Hedgehog pathway inhibitor, taken in combination with LDAC. In the EU, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy. In the U.S. and Canada, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.